Quantitative evaluation of bone marrow angiogenesis in idiopathic myelofibrosis

American Journal of Clinical Pathology

Volumn 126, Issue 2, 2006, Pages 241-247

  Ni, Hongyu ^a,c   Barosi, Giovanni ^b   Hoffman, Ronald ^a  

^a UNIVERSITY OF ILLINOIS   (United States)

^b FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^c Genoptix Inc   (United States)

Author keywords

Angiogenesis; Bone marrow; Idiopathic myelofibrosis; Myeloproliferative disorders

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR; VASCULOTROPIN;

ADULT; AGED; ALLOGENEIC STEM CELL TRANSPLANTATION; ANGIOGENESIS; ARTICLE; BONE MARROW; BONE MARROW BIOPSY; CLINICAL ARTICLE; CONTROLLED STUDY; ENDOTHELIUM CELL; EVALUATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MEGAKARYOCYTE; MORPHOMETRICS; MYELOID METAPLASIA; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS;

EID: 33746702623     PISSN: 00029173     EISSN: None     Source Type: Journal    
DOI: 10.1309/4YGKED5LWFW4AVDV     Document Type: Article

References (31)

1. Bergers G, Benjamin LE. Tumorigenesis and the angiogenic switch. Nat Rev Cancer. 2003;3:401-410.
2. Perez-Atayde AR, Sallan SE, Tedrow U, et al. Spectrum of tumor angiogenesis in the bone marrow of children with acute lymphoblastic leukemia. Am J Pathol. 1997;150:815-821.
3. Fiedler W, Graeven U, Ergun S, et al. Vascular endothelial growth factor, a possible paracrine growth factor in human acute myelogenous leukemia. Blood. 1997;89:1870-1875.
4. Hussong JW, Rodgers GM, Shami PJ. Evidence of increased angiogenesis in patients with acute myeloid leukemia. Blood. 2000;95:309-313.
5. Aguayo A, Kantarjian H, Manshouri T, et al. Angiogenesis in acute and chronic leukemia and myelodysplastic syndromes. Blood. 2000;96:2240-2245.
6. Molica S, Vacca A, Levato D, et al. Angiogenesis in acute and chronic lymphocytic leukemia. Leuk Res. 2004;28;321-324.
7. Vacca A, Ribatti D, Roncali L, et al. Bone marrow angiogenesis and progression in multiple myeloma. Br J Haematol. 1994;87:503-508.
8. Hoffman R, Ravandi F. Myelofibrosis with myeloid metaplasia. In: Hoffman R, Benz E Jr, Shattil S, et al, eds. Hematology: Basic Principles and Practice. 4th ed. New York, NY: Churchill Livingstone; 2005:1255-1276.
9. Barosi G. Myelofibrosis with myeloid metaplasia. Hematol Oncol Clin N Am. 2003;17:1211-1226.
10. Simons M. Integrative signaling in angiogenesis. Mol Cell Biochem. 2004;264:99-102.
11. Di Raimondo F, Azzaro MP, Palumbo GA, et al. Elevated vascular endothelial growth factor (VEGF) serum levels in idiopathic myelofibrosis. Leukemia. 2001;15:976-980.
12. Martyre MC, Le Bousse-Kerdiles MC, Romquin N, et al. Elevated levels of basic fibroblast growth factor in megakaryocytes and platelets from patients with idiopathic myelofibrosis. Br J Haematol. 1997;97:441-448.
13. Mesa RA, Hanson CA, Rajkumar SV, et al. Evaluation and clinical correlation of bone marrow angiogenesis in myelofibrosis with myeloid metaplasia. Blood. 2000;96:3374-3380.
14. Barosi G, Ambrosetti A, Finelli C, et al. The Italian Consensus Conference on Diagnostic Criteria for Myelofibrosis With Myeloid Metaplasia. Br J Haematol. 1999;104:730-737.
15. Weibel ER. Point counting methods. In: Stereological Methods. London, England: Academic Press; 1979:101-161.
16. Practical Methods for Biological Morphometry; vol 1.
17. Devine SM, Hoffman R, Verma A, et al. Allogeneic blood cell transplantation following reduced-intensity conditioning is effective therapy for older patients with myelofibrosis with myeloid metaplasia. Blood. 2002;99:2255-2258.
18. Weidner N, Semple JP, Welch WR, et al. Tumor angiogenesis and metastasis: correlation in invasive breast carcinoma. N Engl J Med. 1991;324:1-8.
19. Kvasnicka HM, Thiele J. Bone marrow angiogenesis: methods of quantification and change evolving in chronic myeloproliferative disorders. Histol Histopathol. 2004;19:1245-1260.
20. Fox SB, Leek RD, Weekes MP, et al. Quantitation and prognostic value of breast cancer angiogenesis: comparison of microvessel density, Chalkley count, and computer image analysis. J Pathol. 1995;177:275-283.
21. Chalkley HW. Method for the quantitative morphologic analysis of tissues. J Natl Cancer Inst. 1943;4:47-53.
22. Dickinson AJ, Fox SB, Persad RA, et al. Quantification of angiogenesis as an independent predictor of prognosis in invasive bladder carcinomas. Br J Urol. 1994;74:762-766.
23. Vermeulen PB, Gasparini G, Fox SB, et al. Second international consensus on the methodology and criteria of evaluation of angiogenesis quantification in solid human tumours. Eur J Cancer. 2002;38:1564-1579.
24. Chou JM, Li CY, Tefferi A. Bone marrow immunohistochemical studies of angiogenic cytokines and their receptors in myelofibrosis with myeloid metaplasia. Leuk Res. 2003;27:499-504.
25. Ferrara N. VEGF and the quest for tumour angiogenesis factors. Nat Rev Cancer. 2002;2:795-803.
26. Friesel RE, Maciag T. Molecular mechanisms of angiogenesis: fibroblast growth factor signal transduction. FASEB J. 1995;9:919-925.
27. Grunewald M, Avraham I, Dor Y, et al. VEGF-induced adult neovascularization: recruitment, retention, and role of accessory cells. Cell. 2006;124:175-189.
28. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med. 1995;1:27-31.
29. Gunsilius E, Duba HC, Petzer AL, et al. Evidence from a leukaemia model for maintenance of vascular endothelium by bone-marrow-derived endothelial cells. Lancet. 2000;355:1688-1691.
30. Massa M, Rosti V, Ramajoli I, et al. Circulating CD34+, CD133, and vascular endothelial growth factor receptor 2-positive endothelial progenitor cells in myelofibrosis with myeloid metaplasia. J Clin Oncol. 2005;23:5688-5695.
31. Guardiola P, Anderson JE, Bandini G, et al. Allogeneic stem cell transplantation for agnogenic myeloid metaplasia: a European Group for Blood and Marrow Transplantation, Societe Francaise de Greffe de Moelle, Gruppo Italiano per il Trapianto del Midollo Osseo, and Fred Hutchinson Cancer Research Center collaborative study. Blood. 1999;93:2831-2838.